Anixa Biosciences Inc.

AI Score

0

Unlock

2.15
-0.04 (-1.83%)
At close: Jan 14, 2025, 3:59 PM
2.13
-0.93%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 2
Market Cap 69.19M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.39
PE Ratio (ttm) -5.51
Forward PE n/a
Analyst Buy
Ask 2.44
Volume 126,201
Avg. Volume (20D) 107,337
Open 2.16
Previous Close 2.19
Day's Range 2.07 - 2.24
52-Week Range 2.07 - 5.13
Beta undefined

About ANIX

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the t...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 7, 1983
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ANIX

Analyst Forecast

According to 3 analyst ratings, the average rating for ANIX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 365.12% from the latest price.

Buy 66.67%
Hold 0.00%
Sell 0.00%
Stock Forecasts
1 month ago · Source
+4.58%
Anixa Biosciences shares are trading higher after ... Unlock content with Pro Subscription